论文部分内容阅读
目的分析母牛分枝杆菌对降低耐多药性肺结核患者血清血管活性肠肽(VIP)、白细胞介素-17(IL-17)水平的作用。方法选取2011年至2014年耐多药性肺结核患者48例,随机分成实验组和对照组,每组24例。对照组患者行复治抗结核治疗方案3DRt SLE/6Drt E治疗,在此基础上实验组患者行母牛分枝杆菌肌注治疗,疗程均为9个月。观察治疗前后,患者血清VIP、IL-17水平的变化。结果治疗前,实验组和对照组患者血清VIP、IL-17水平比较差异未见统计学意义(P>0.05);治疗后,与对照组比较,实验组患者血清VIP、IL-17水平降低更为明显,差异有统计学意义(P<0.05)。结论行母牛分枝杆菌肌注治疗能明显降低耐多药性肺结核患者血清VIP、IL-17水平,具有很好的临床疗效。
Objective To analyze the effect of Mycobacterium vaccae on decreasing the levels of serum vasoactive intestinal peptide (VIP) and interleukin-17 (IL-17) in patients with multi-drug resistant pulmonary tuberculosis. Methods Forty-eight patients with multidrug-resistant pulmonary tuberculosis from 2011 to 2014 were randomly divided into experimental group and control group with 24 cases in each group. Patients in the control group received retreatment of anti-tuberculosis treatment program 3DRt SLE / 6Drt E treatment, on the basis of which the experimental group received intramuscular injection of Mycobacterium vaccae for 9 months. Changes of serum VIP and IL-17 levels before and after treatment were observed. Results Before treatment, the levels of serum VIP and IL-17 in the experimental group and the control group were not significantly different (P> 0.05). After treatment, the levels of serum VIP and IL-17 in the experimental group were lower than those in the control group For obvious, the difference was statistically significant (P <0.05). Conclusion Mycobacterium vaccae intramuscular injection therapy can significantly reduce the serum levels of VIP and IL-17 in patients with multi-drug-resistant pulmonary tuberculosis and has good clinical efficacy.